Skip to content
ClinCalc Pro
Menu
ACE Inhibitor

Ramipril

Brand names: Tritace

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension, heart failure, diabetic and non-diabetic nephropathy, and for cardiovascular risk reduction in patients with established vascular disease.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits ACE, reducing the conversion of angiotensin I to angiotensin II, thereby causing vasodilatation, lowering aldosterone and reducing blood pressure and cardiac afterload.

Prescribing in practice

  • Angioedema is an uncommon but potentially life-threatening reaction that mandates immediate, permanent discontinuation, and the drug is contraindicated in pregnancy.
  • Check renal function and potassium before starting and after dose changes, as it can cause hyperkalaemia and acute kidney injury, particularly with NSAIDs, potassium-sparing agents or renal artery stenosis.
  • Counsel on the common dry cough and the risk of first-dose hypotension, especially in volume-depleted patients or those on diuretics.

Monitoring

Monitor blood pressure, renal function and serum potassium before initiation and after each dose increase, and periodically thereafter.

Counselling the patient

  • A persistent dry cough can occur; tell your doctor if it troubles you.
  • Do not use this medicine if you are or might become pregnant.
  • Report any swelling of the face, lips or throat immediately.

Evidence & guidelines

Ramipril's cardiovascular benefit is supported by the HOPE trial and it is recommended in NICE hypertension and heart failure guidance.

Reference: NICE NG136 (Hypertension); HOPE Trial (NEJM 2000); MHRA Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.